Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. [electronic resource]
Producer: 20100304Description: 815-21 p. digitalISSN:- 1527-7755
- Age Factors
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Alkylating -- administration & dosage
- Comorbidity
- Europe -- epidemiology
- Female
- Gene Expression Regulation, Leukemic
- Heart Diseases -- mortality
- Humans
- Hydrazines -- administration & dosage
- Infusions, Intravenous
- Kaplan-Meier Estimate
- Karyotyping
- Leukemia, Myeloid, Acute -- drug therapy
- Liver Diseases -- mortality
- Lung Diseases -- mortality
- Male
- Middle Aged
- Prospective Studies
- Risk Assessment
- Risk Factors
- Sulfonamides -- administration & dosage
- Treatment Outcome
- United States -- epidemiology
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.